Redeye gives a brief comment on the newly published article comparing AroCell TK 210 ELISA with competing TK1 assays. In short, we do not view the case any differently at the moment, and judge these news to be in line with the company's clinical validation strategy. Still, it acts as an important tool for eventual commercial introduction at a larger scale.